Search Bar & Filters
Found 134 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying calderasib alone and in combination with cetuximab to treat advanced solid tumors in people with the KRAS G12C mutation. The study aims to find out how many patients respond to these treatments and to evaluate their safety and tolerability. This phase 2 trial is tumor-agnostic, meaning it includes various solid tumors except colorectal cancer that have progressed despite standard treatment. Participants receive calderasib by mouth, either alone or with cetuximab given by intravenous infusion every two weeks. There is no set maximum number of treatment cycles, and participants continue until they meet criteria to stop treatment. The study is randomized and open-label, comparing the two treatment approaches in parallel groups. During the study, participants will be monitored for tumor response, adverse events, and reasons for discontinuing treatment over about 76 months. Researchers will assess progression-free survival, duration of response, and overall survival. Safety evaluations and regular clinical visits will support ongoing monitoring throughout the trial.
Actively Recruiting
Researchers are evaluating the effects of NB-4746 compared with placebo in adults with amyotrophic lateral sclerosis ALS. This trial aims to understand the safety, side effects, how NB-4746 moves through the body, and changes in a blood marker called neurofilament light NfL, which indicates nerve cell damage. The study is divided into two parts and includes an optional open-label extension. In Part A, participants are randomly assigned to receive either a low dose of NB-4746, a high dose of NB-4746, or placebo capsules taken twice daily for about one month. In Part B, participants are again randomized to receive NB-4746 at a dose determined based on Part A results or placebo capsules twice daily for about twelve weeks. After completing Part A or B, participants may opt to continue treatment in an open-label extension lasting up to one year. Participants will be monitored throughout the trial with regular health checks focusing on ALS symptoms and overall wellbeing. Researchers will track adverse events, measure blood levels of NB-4746, and assess changes in neurofilament light to evaluate nerve damage. Safety and tolerability will be evaluated from enrollment through the treatment periods, with ongoing monitoring during the extension phase.
Actively Recruiting
Researchers are evaluating IBI354, a recombinant anti-HER2 monoclonal antibody-camptothecin derivative conjugate, in people with locally advanced unresectable or metastatic solid tumors. This Phase 12, open-label, multicenter study aims to assess the safety, tolerability, and dose-limiting toxicities to find the maximum tolerated or administered dose and the recommended Phase 2 dose of IBI354. The study also explores the drugs effectiveness and safety in this patient population. Participants receive sequential doses of IBI354 through a single-arm treatment plan. The study includes a Phase 1a dose escalation period to determine safety and dosing limits, followed by Phase 1b2 periods focusing on selected solid tumors expressing HER2. Treatment schedules and dosing details are designed to monitor tolerability and explore efficacy outcomes over time. During the study, participants undergo various assessments including monitoring for adverse events, dose-limiting toxicities within the first 21 days of treatment, and evaluation of objective response rate, duration of response, progression-free survival, and overall survival for up to two years. Safety evaluations continue up to 30 days after the last dose. Participants provide written informed consent and undergo cardiac function monitoring before treatment, with ongoing evaluations throughout their participation, which lasts as long as the study and follow-up periods continue.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of IMP1734, a PARP1 selective inhibitor, in people with advanced solid tumors. This study includes patients with breast cancer, metastatic prostate cancer, ovarian cancer, and other solid tumors who have previously received certain treatments. The goal is to find an optimal dose for future clinical development by studying how the drug affects the body and how the body processes it. The study has two parts Part 1 involves gradually increasing doses of IMP1734 given as a daily oral tablet to identify the highest safe dose or maximum achievable dose. This includes testing the drug alone and in combination with other treatments for specific cancers like metastatic prostate, ovarian, and breast cancer. Part 2 focuses on refining the dose to find the best amount for future studies. Treatment can last up to three years after the first dose. Participants will be monitored closely with assessments of side effects, blood tests to study drug levels and effects, and evaluations of tumor response using standard criteria. Safety monitoring continues up to 30 days after the last dose. Researchers measure how well the drug is tolerated and its impact on the cancer over time. The total participation may extend up to three years, with ongoing evaluations during this period.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, immune response, and early clinical effects of BNT3212, both alone and combined with pumitamig, in adults with advanced solid tumors who have exhausted other treatment options. This first-in-human, open-label study includes dose escalation and expansion phases to find the best dose and assess how the treatments work across different tumor types. The study is divided into four parts Part A and Part B focus on BNT3212 as a single therapy, with dose escalation followed by dose expansion in specific tumor types. Parts C and D evaluate the combination of BNT3212 with a fixed dose of pumitamig, again starting with dose escalation and then expansion cohorts. Treatments are given by intravenous infusion, and doses are adjusted to find the maximum tolerated dose and recommended dose for further study. Participants will undergo regular monitoring including safety assessments, blood tests to study drug levels and immune reactions, and imaging to measure tumor response. Researchers will track side effects, treatment interruptions, and response rates over approximately 31 months. The study also measures progression-free and overall survival. Continuous evaluation of safety and clinical data supports participant well-being throughout the trial.
Actively Recruiting
Researchers are studying the best steroid dose to treat acute T cell mediated rejection TCMR in people who have had kidney or kidney-pancreas transplants. TCMR is a type of rejection where the bodys immune system attacks the transplanted organ, which can cause serious complications or organ failure. This international, multi-center trial aims to find the lowest effective and safe steroid dose to manage this condition, addressing a long-standing question in transplant care. The trial compares four treatment approaches that differ in doses of intravenous methylprednisolone IV MP and oral prednisone taper. Participants receive either a high or low dose of IV MP for three days followed by a high or low dose of oral prednisone for seven days, then return to standard prednisone. This factorial design allows evaluation of both drugs dose effects. The study is sponsored by the University of Sydney and involves collaboration among several international transplant societies. Participants will be closely monitored with biopsies and blood tests to assess rejection resolution and kidney function over 12 weeks. Researchers will also track survival, kidney filtration rates, urine protein levels, infection rates, quality of life, and other health outcomes up to 48 weeks. The study includes regular visits and evaluations to ensure safety and collect data on treatment effects and side effects during the trial period.
Actively Recruiting
Open-label Dose-Escalation Study of Oral D3S-003 for Advanced Solid Tumors with KRAS p.G12D Mutation
Researchers are evaluating D3S-003, an oral drug, in a first-in-human Phase 1 clinical trial for participants with advanced solid tumors that have a specific KRAS p.G12D mutation. This trial aims to assess the safety, tolerability, how the drug is processed by the body, its biological effects, and early signs of how well it might work. Participants must have cancers that have not responded to standard treatments or have no effective standard options, and tumors that can be measured by imaging. The study includes two parts of dose escalation to find the best dosing schedule once daily and twice daily dosing of D3S-003. Participants will receive the drug orally with doses gradually increased to evaluate safety and identify the maximum tolerated dose and recommended Phase 2 dose. The treatment period can last up to approximately seven months or until disease progression or unacceptable side effects occur. During the study, participants will have regular monitoring for side effects and safety from the screening visit until 30 days after the last dose. Researchers will measure drug levels in the blood and evaluate tumor response using standardized criteria. The primary outcomes include the number of participants experiencing dose-limiting toxicities and adverse events. The trial will last until January 2028, with frequent assessments during treatment cycles of 21 days each.
Actively Recruiting
Researchers are studying DB-1303BNT323, a biological drug, in a Phase 12a trial to evaluate its safety and tolerability in adults with advanced or metastatic malignant solid tumors that express HER2. The trial focuses on patients whose tumors are refractory to standard treatments or have no available standard options. This first-in-human study includes both a dose-escalation phase to find the maximum tolerated dose and a dose-expansion phase to further assess safety and explore efficacy in selected tumors. Participants receive DB-1303BNT323 intravenously once every three weeks at various dose levels, including a randomized comparison of doses during some expansion cohorts. Additional treatments may include ritonavir or itraconazole to assess drug interactions, and in some cases, DB-1303BNT323 is combined with Pertuzumab. The study is open-label and multicenter, with dosing continuing according to the protocols schedule. During the trial, participants undergo regular assessments including safety monitoring for adverse events, dose-limiting toxicities, and serious adverse events up to about one year post-treatment. Researchers measure tumor response using RECIST 1.1 criteria and evaluate pharmacokinetics and pharmacodynamics. Organ function, heart performance, and life expectancy are also monitored throughout this period. The estimated study completion is in October 2027.
Actively Recruiting
Researchers are studying the safety and effects of a mutant-selective drug called RLY-2608, which targets the PI3K protein, in adults and children with PIK3CA Related Overgrowth Spectrum PROS and malformations caused by PIK3CA mutations. This Phase 2 study is divided into three parts dose selection, exploration of different participant groups, and a randomized, double-blinded comparison against placebo. The study aims to understand how this drug works in these rare conditions involving abnormal tissue growth. Participants will receive oral doses of RLY-2608 across different age groups, including adults and children as young as 2 years old. The study includes dose escalation for younger children and dose expansion cohorts for various subpopulations. The final part randomizes participants aged 6 years and older to receive either RLY-2608 or a placebo. Dosing schedules and groups are tailored by age and condition, with careful monitoring throughout. During the trial, participants will provide tissue or fluid samples to assess PIK3CA mutations. Researchers will track side effects, safety labs, vital signs, and heart function regularly during treatment cycles. They will measure changes in lesion size and response rates at baseline and various points up to 24 weeks, with additional long-term follow-up for response duration and drug levels in the blood. Quality of life and symptom improvements will also be evaluated monthly during treatment. The study continues until 2031, with ongoing safety and efficacy assessments.
Actively Recruiting
This research aims to evaluate disease status in children newly diagnosed with high-grade glioma that have a TRK fusion. It is a pilot study focusing on children up to 21 years old, assessing disease control and survival rates. The study also examines the safety of larotrectinib given with chemotherapy or after focal radiation therapy in this group. Participants will receive larotrectinib orally twice daily at a dose based on body surface area, in 28-day cycles. After 2 cycles of larotrectinib alone, patients showing a complete or continued complete response will continue larotrectinib as maintenance therapy for up to 12 cycles, with possible extension to 24 cycles if beneficial. Those with partial response or stable disease may receive additional chemotherapy or focal radiation depending on age and clinical factors. A surgical cohort will receive larotrectinib for 3-5 days before surgery followed by larotrectinib treatment. During the study, participants will be closely monitored for disease control using imaging and for safety by tracking side effects and adverse events. Researchers will measure drug levels in blood and tumor tissue in the surgical group. The main outcomes include disease control after 2 cycles and treatment-related side effects, with survival rates assessed over time. Participation involves regular visits, treatment cycles, and follow-up evaluations for up to several years.
1-10 of 134
1